Xencor, Inc. (NASDAQ:XNCR) Shares Sold by State of Tennessee Treasury Department

State of Tennessee Treasury Department lowered its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 2.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,983 shares of the biopharmaceutical company’s stock after selling 915 shares during the quarter. State of Tennessee Treasury Department owned about 0.06% of Xencor worth $1,463,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in XNCR. Penserra Capital Management LLC boosted its holdings in shares of Xencor by 169.4% in the 4th quarter. Penserra Capital Management LLC now owns 1,320 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 830 shares during the period. Vantage Consulting Group Inc acquired a new position in Xencor in the fourth quarter valued at approximately $67,000. Veriti Management LLC bought a new stake in Xencor during the 4th quarter valued at $93,000. Nisa Investment Advisors LLC boosted its position in Xencor by 10.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,100 shares of the biopharmaceutical company’s stock worth $135,000 after acquiring an additional 300 shares during the period. Finally, Meeder Asset Management Inc. grew its stake in shares of Xencor by 13,943.8% in the first quarter. Meeder Asset Management Inc. now owns 4,494 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 4,462 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

NASDAQ:XNCR opened at $37.24 on Friday. The company has a fifty day moving average of $40.51. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -33.55 and a beta of 0.65. Xencor, Inc. has a 1-year low of $27.38 and a 1-year high of $58.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.92 and a quick ratio of 5.92.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, May 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.72. The company had revenue of $33.97 million during the quarter, compared to analyst estimates of $13.05 million. Xencor had a negative net margin of 51.29% and a negative return on equity of 11.11%. On average, analysts anticipate that Xencor, Inc. will post -1.57 EPS for the current year.

Several equities research analysts recently weighed in on the stock. Barclays upped their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an “underweight” rating in a report on Wednesday, February 24th. Royal Bank of Canada upped their price target on shares of Xencor from $48.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 24th. Raymond James upgraded shares of Xencor from a “market perform” rating to an “outperform” rating and set a $58.00 price objective on the stock in a research note on Wednesday, February 24th. Zacks Investment Research raised Xencor from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a report on Tuesday, May 11th. Finally, SVB Leerink reiterated a “buy” rating and set a $57.00 price target on shares of Xencor in a research report on Sunday, May 9th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. Xencor has an average rating of “Buy” and an average price target of $50.33.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies.

See Also: 52-Week High/Low

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.